Pure Global

A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma - Trial NCT06405425

Access comprehensive clinical trial information for NCT06405425 through Pure Global AI's free database. This Phase 2 trial is sponsored by Sichuan Baili Pharmaceutical Co., Ltd. and is currently Not yet recruiting. The study focuses on Urothelial Carcinoma. Target enrollment is 52 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06405425
Phase 2
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06405425
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 + PD-1 Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Study Focus

Urothelial Carcinoma

BL-B01D1

Interventional

drug

Sponsor & Location

Sichuan Baili Pharmaceutical Co., Ltd.

Shanghai, China

Timeline & Enrollment

Phase 2

May 01, 2024

May 01, 2026

52 participants

Primary Outcome

Objective Response Rate (ORR)

Summary

This study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1
 combination therapy in patients with locally advanced or metastatic urothelial carcinoma.

ICD-10 Classifications

Carcinoma in situ: Other and unspecified urinary organs
Malignant neoplasm of ureter
Malignant neoplasms of urinary tract
Malignant neoplasm: Overlapping lesion of urinary organs
Malignant neoplasm: Urethra

Data Source

ClinicalTrials.gov

NCT06405425

Non-Device Trial